StockData
Organon & Co. logo

Organon & Co. (OGN) company profile

OGNNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/3013% above fair value
$13.90+0.00 (0.00%)

Close on Nov 16, 2026Market cap $3.65BP/E 18.1Yield 2.45%

About Organon

Pharmaceutical Preparations, SIC 2834

Organon & Co. is a healthcare company that develops and supplies pharmaceutical treatments centered on women’s health and general medicine. Its business is organized into women’s health, biosimilars, and established brands. The women’s health segment focuses on prescription contraception and fertility treatments, including implants, vaginal rings, and follicle-stimulating injections. Its biosimilar offerings treat immunology and oncology conditions, while the established brands portfolio covers cardiovascular, respiratory, dermatology, bone health, and non-opioid pain medications. Organon distributes its products to drug wholesalers, retailers, hospitals, government agencies, and managed care institutions such as pharmacy benefit managers and health maintenance organizations.

The company distributes medications across more than 140 countries and territories, with its women’s health offerings available in over 90 international markets. It operates six manufacturing facilities situated in Belgium, Brazil, Indonesia, Mexico, the Netherlands, and the United Kingdom. Organon employs over 10,000 people globally, with around 1,500 workers located in the United States and Puerto Rico. The provided text does not state the company's headquarters.

Summary of the business section of Organon's latest annual report, written by StockData.

Company profile

Company

Legal name
Organon & Co.
Founded
1923
Headquarters
Jersey City, NJ
Address
30 Hudson Street, Fl 33 07302
Phone
(551) 430-6000
Employees
10,000, Dec 31, 2025
Industry
Pharmaceutical Preparations
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Florham Park, New Jersey

Stock & identifiers

Ticker
OGN
Exchange
NYSE
IPO date
May 14, 2021
Shares outstanding
263M, Oct 23, 2026
Public float
$2.50B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1821825
CUSIP
68622V106
ISIN
US68622V1061
FIGI
BBG00ZQRGW24
Share class FIGI
BBG00ZQRGW42
LEI
549300AMCKY57OK2CO56
EIN
46-4838035

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Carrie Smith CoxExecutive Chair, Director90,338
Kevin AliChief Executive Officer, Director282,731
Juliana Papa DrinaneHead of Mfg & Supply35,239
Joseph T. Morrissey Jr.CEO153,316
Ferreira Juan Camilo ArjonaHead of R&D & CMO41,565
Lynette HolzbaurSVP and Corporate Controller3,901
Vittorio NisitaHead of Global Business Svcs70,619
Rachel A. StahlerChief Information Officer110,256
Matthew M. WalshChief Financial Officer202,707
Kirke WeaverGen. Counsel & Corp. Secy.85,602
Daniel KarpExecutive VP, Corp. Dev.71,653
Aaron FalcioneChief Human Resources Officer96,378
Kathryn DiMarcoCorporate Controller35,917
Alan EzekowitzDirector–
Shalini SharpDirector2
Cynthia M. PattonDirector–
Ramona SequeiraDirector100
Deborah R. LeoneDirector10
Philip OzuahDirector–
Robert EssnerDirector–
Rochelle B. LazarusDirector633
Helene D. GayleDirector–
Grace Puma WhitefordDirector5

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Joseph Morrissey
$5.77M$2.73M$4.15M$2368$15636
FY2025
Kevin Ali
$15.81M-$9.84M$4.15M$2368$15636
FY2024$17.12M$16.38M$4.42M$4805$12975
FY2023$14.83M-$553.77K$4.07M$4371$12639
FY2022$13.53M$11.73M$4.13M$7965$12052
FY2021$18.55M$14.26M$5.31M$8372$11488

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Joseph Morrissey
Interim Chief Executive Officer
$819.23K$3.37M$750.00K$602.43K$235.37K$5.77M+40%
Matthew Walsh
EVP and Chief Financial Officer
$919.23K$3.04M$962.50K$532.80K$235.50K$5.69M-1%
Juan Camilo Arjona Ferreira, M.D.
EVP and Head of R&D and Chief Medical Officer
$734.62K$1.89M$600.00K$437.76K$157.46K$3.82M+6%
Rachel Stahler
EVP and Chief Digital & Growth Officer
$706.92K$1.73M$550.00K$411.84K$147.92K$3.55M–
Kirke Weaver
EVP, General Counsel and Corporate Secretary
$676.92K$1.73M$550.00K$394.56K$186.56K$3.54M+1%
Kevin Ali
Former Chief Executive Officer
$1.09M$10.25M$3.25M–$1.22M$15.81M-8%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had over 10,000 employees worldwide with approximately 1,500 (15%) employees in the United States, including Puerto Rico.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?